22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately ...
20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...
21 September 2023 - The agenda for this week's HTA Review Reference Committee meeting is now available. ...
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...
20 September 2023 - The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada ...
19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...
18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...
18 September 2023 - The Albanese Government is listing a new form of fast-acting insulin on the PBS from 1 ...
15 September 2023 - The agenda for the HTA Review Reference Committee meeting of 14 September 2023 is now available. ...
14 September 2023 - The first treatment to be recommended by NICE for treating acute migraine will soon be available on ...
14 September 2023 - The Department has today published version 4 of the agenda for the November 2023 PBAC meeting. ...
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...
13 September 2023 - BMS, the supplier of lomustine, a treatment used for a type of brain cancer called glioma, is ...
11 September 2023 - NICE has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now ...